Table 1.

Characteristics of Patients and Breast Cancers in Our Study

	Total (N=259)	HER2+ (N=73)	Luminal (N=112)	TNBC (N=74)	p value
Age					0.33
Median (Range)	50 (24–84)	49 (26–84)	49 (32–79)	51 (24–77)
Histology					0.001
Ductal	225 (86.9%)	71 (97.3%)	92 (82.1%)	62 (83.8%)
Lobular	12 (4.6%)	0 (0.0%)	11 (9.8%)	1 (1.4%)
Mixed Ductal & Lobular	20 (7.7%)	2 (2.7%)	9 (8.0%)	9 (12.2%)
Other	2 (0.8%)	0 (0.0%)	0 (0.0%)	2 (2.7%)
Biopsy Tumor Grade					<0.001
1 (Well differentiated)	8 (3.1%)	1 (1.4%)	7 (6.3%)	0 (0.0%)
2 (Moderately differentiated)	98 (38.1%)	26 (36.6%)	57 (50.9%)	15 (20.3%)
3 (Poorly differentiated)	151 (58.8%)	44 (62.0%)	48 (42.9%)	59 (79.7%)
Not Done	2	2	0	0
Clinical T Category					0.04
cT1	15 (5.8%)	6 (8.2%)	2 (1.8%)	7 (9.5%)
cT2	147 (56.8%)	42 (57.5%)	59 (52.7%)	46 (62.2%)
cT3	71 (27.4%)	15 (20.5%)	40 (35.7%)	16 (21.6%)
cT4	26 (10.0%)	10 (13.7%)	11 (9.8%)	5 (6.8%)
Clinical N Category					0.14
cN0	97 (37.5%)	24 (32.9%)	40 (35.7%)	33 (44.6%)
cN1	134 (51.7%)	42 (57.5%)	61 (54.5%)	31 (41.9%)
cN2	18 (6.9%)	3 (4.1%)	10 (8.9%)	5 (6.8%)
cN3	10 (3.9%)	4 (5.5%)	1 (0.9%)	5 (6.8%)
Clinical Stage					0.27
Stage I	7 (2.7%)	2 (2.7%)	1 (0.9%)	4 (5.4%)
Stage II	160 (61.8%)	46 (63.0%)	66 (58.9%)	48 (64.9%)
Stage III	92 (35.5%)	25 (34.2%)	45 (40.2%)	22 (29.7%)
pCR					<0.001
No	185 (71.4%)	34 (46.6%)	104 (92.9%)	47 (63.5%)
Yes	74 (28.6%)	39 (53.4%)	8 (7.1%)	27 (36.5%)
RCB Class					<0.001
Missing	81	13	46	22
0	74 (41.6%)	39 (65.0%)	8 (12.1%)	27 (51.9%)
I	18 (10.1%)	7 (11.7%)	6 (9.1%)	5 (9.6%)
II	48 (27.0%)	10 (16.7%)	26 (39.4%)	12 (23.1%)
III	38 (21.3%)	4 (6.7%)	26 (39.4%)	8 (15.4%)

IDC=invasive ductal carcinoma, ILC=invasive lobular carcinoma, HER2+=human epidermal growth factor receptor 2+, TNBC=triple negative breast cancer, pCR=pathological complete response, RCB=residual cancer burden